WCLC 2022 | Targeting KRAS: future directions

Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, discusses developments in KRAS as a druggable target. Currently, only KRAS inhibitors targeting the KRASG12C mutation have been approved, however pan-KRAS inhibitors are currently in development. Additionally, KRAS inhibitors that cross the blood-brain barriers (BBB) are under investigation to increase intracranial activity. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.